E

Enhabit

Advises and builds healthier, efficient homes

Nurse Practitioner - Hospice

Full-TimeDeadline 9/25/27
No salary listed
Mid
Aiken, SC, USA
In Person
Medical, Clinical & VeterinaryAdvanced Practice Providers

About the job

Requirements
  • Graduation from an approved school and licensure as a nurse practitioner in the state of practice.
  • Demonstrated knowledge of regulatory requirements, including Medicare conditions of participation.
  • Basic technology skills, including operation of a mobile device.
  • A valid state driver's license.
  • Automobile liability insurance as required by law.
  • Dependable transportation in good working condition.
  • Ability to safely drive an automobile in all types of weather conditions.
  • Current CPR certification.
Responsibilities
  • Provide medical care to hospice patients.
  • Determine hospice eligibility and manage patients' pain and symptoms.
  • Participate in hospice patient care as a member of the interdisciplinary team.
Desired Qualifications
  • At least five years of nursing experience, including a minimum of one year in hospice.
  • At least three years of clinical registered nurse practitioner experience.

About the company

What Enhabit does: Enhabit helps homeowners, utilities, and local governments create better living spaces that are efficient, healthy, and safe. They combine hands-on field work with practical advice to improve homes and communities. How its products work: The company carries out on-site projects to upgrade efficiency, safety, and healthy living features, while also providing guidance and design solutions to meet local needs. How it is different from competitors: Enhabit emphasizes social impact and collaborative work with multiple stakeholders (homeowners, utilities, and governments), delivering end-to-end services from assessment and planning to hands-on implementation. What its goal is: to build strong, thriving, and equitable communities by making everyday living spaces better for everyone.

Company Size

1-10

Company Stage

N/A

Total Funding

N/A

Headquarters

Portland, Oregon

Founded

2009

Get referred to Enhabit

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 1.9% to $264.8 million, with hospice up 6.2%.
  • Q4 2025 adjusted EBITDA grew 11.6% year over year to $28.0 million.
  • Hospice ADC rose 9.9% in Q4 2025, signaling durable patient demand.

What critics are saying

  • CMS finalized a 1.3% 2026 home health payment cut, pressuring margins immediately.
  • The company suspended 2026 guidance after the Kinderhook deal, reducing accountability and transparency.
  • Private ownership under Kinderhook shifts strategic control away from public shareholders and employees.

What makes Enhabit unique

  • Kinderhook’s $1.1 billion take-private on May 15, 2026 validates Enhabit’s platform.
  • Enhabit spans 249 home health and 117 hospice locations across 34 states.
  • Hospice growth outpaced home health in 2025, strengthening its mixed post-acute model.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Flexible Spending Accounts
  • Paid Vacation
  • Performance Bonus
  • Professional Development Budget

Company News

Yahoo Finance
Mar 5th, 2026
Enhabit matches Q4 earnings estimates, shares surge 47.5% this year

Enhabit, a provider of home health and hospice services, reported fourth-quarter earnings of $0.14 per share, matching the Zacks Consensus Estimate. This represents an improvement from $0.04 per share a year earlier and marks the fourth consecutive quarter the company has met or exceeded earnings expectations. Revenues reached $270.4 million for the quarter ended December 2025, surpassing consensus estimates by 0.40% and up from $258.2 million in the prior year. The company has topped revenue estimates in two of the last four quarters. Enhabit shares have gained 47.5% year-to-date, significantly outperforming the S&P 500's 0.4% decline. The stock currently carries a Zacks Rank of 2 (Buy), suggesting continued outperformance in the near term.